Mobius Therapeutics, LLC

A device used in cardiac surgery and a powered-arm prosthesis will both be regulated as moderate-risk, class II devices, US FDA affirmed in a pair of Oct. 17 Federal Register notices. Both classificat

The worldwide glaucoma market, worth over $4 billion annually, has been dominated for decades by drug therapy, which accounts for approximately 95% of the total market. The emergence of a high-growth

by Mary Stuart Micardia Anticipates the Shape of Things to Come In medical devices, one size rarely fits all, and when it come to the type of heart valve disease that arises from heart failure, one si

A preview of the emerging health care companies profiled in the current issue of START-UP: Windhover’s Review of Emerging Medical Ventures This month's profile group: The Eyes Still Have It Alacrity